Accès gratuit
Numéro
Med Sci (Paris)
Volume 29, Mars 2013
Mucormycoses
Page(s) 25 - 30
Section M/S Revues
DOI https://doi.org/10.1051/medsci/201329s106
Publié en ligne 13 mars 2013
  1. Bitar D, Cauteren D Van, Lanternier F, et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997–2006. Emerg Infect Dis 2009 ; 15 : 1395–1401. [CrossRef] [PubMed] [Google Scholar]
  2. Horn DL, Neofytos D, Anaissie EJ, et al. Epidemiology and outcomes of candidemia in 2019 patients : data from the prospective antifungal therapy alliance registry. Clin Infect Dis 2009 ; 48 : 1695–1703. [CrossRef] [PubMed] [Google Scholar]
  3. Skiada A, Pagano L, Groll A, et al. Zygomycosis in Europe : analysis of 230 cases accrued by the registry of the European Confederation of Medical Mycology (ECMM) Working Group on Zygomycosis between 2005 and 2007. Clin Microbiol Infect 2011 ; 17 : 1859–1867. [CrossRef] [PubMed] [Google Scholar]
  4. Lanternier F, Dannaoui E, Morizot G, et al. A global analysis of mucormycosis in France : the RetroZygo Study (2005–2007). Clin Infect Dis 2012 ; 54 : S35–S43. [CrossRef] [PubMed] [Google Scholar]
  5. Ibrahim AS, Spellberg B, Walsh TJ, et al. Pathogenesis of mucormycosis. Clin Infect Dis 2012 ; 54 : S16–S22. [CrossRef] [PubMed] [Google Scholar]
  6. Chamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clin Infect Dis 2008 ; 47 : 503–509. [CrossRef] [PubMed] [Google Scholar]
  7. Roilides E, Kontoyiannis DP, Walsh TJ. Host defenses against zygomycetes. Clin Infect Dis 2012 ; 54 : S61–S66. [CrossRef] [PubMed] [Google Scholar]
  8. Rammaert B, Lanternier F, Poirée S, et al. Diabetes and mucormycosis : a complex interplay. Diabetes Metab 2012 ; 38 : 193–204. [CrossRef] [PubMed] [Google Scholar]
  9. Ibrahim AS, Gebremariam T, Lin L, et al. The high affinity iron permease is a key virulence factor required for Rhizopus oryzae pathogenesis. Mol Microbiol 2010 ; 77 : 587–604. [CrossRef] [PubMed] [Google Scholar]
  10. Yohai RA, Bullock JD, Aziz AA, et al. Survival factors in rhino-orbital-cerebral mucormycosis. Surv Ophthalmol 1994 ; 39 : 3–22. [CrossRef] [PubMed] [Google Scholar]
  11. Almyroudis NG, Sutton DA, Linden P, et al. Zygomycosis in solid organ transplant recipients in a tertiary transplant center and review of the literature. Am J Transplant 2006 ; 6 : 2365–2374. [CrossRef] [PubMed] [Google Scholar]
  12. Mohindra S, Mohindra S, Gupta R, et al. Rhinocerebral mucormycosis : the disease spectrum in 27 patients. Mycoses 2007 ; 50 : 290–296. [CrossRef] [PubMed] [Google Scholar]
  13. Lee FY, Mossad SB, Adal KA. Pulmonary mucormycosis : the last 30 years. Arch Intern Med 1999 ; 159 : 1301–1309. [CrossRef] [PubMed] [Google Scholar]
  14. Tedder M, Spratt JA, Anstadt MP, et al. Pulmonary mucormycosis : results of medical and surgical therapy. Ann Thorac Surg 1994 ; 57 : 1044–1050. [CrossRef] [PubMed] [Google Scholar]
  15. Arikan S, Sancak B, Alp S, et al. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus. Med Mycol 2008 ; 46 : 567–573. [CrossRef] [PubMed] [Google Scholar]
  16. Pagano L, Offidani M, Fianchi L, et al. Mucormycosis in hematologic patients. Haematologica 2004 ; 89 : 207–214. [PubMed] [Google Scholar]
  17. Singh N, Aguado JM, Bonatti H, et al. Zygomycosis in solid organ transplant recipients : a prospective, matched case-control study to assess risks for disease and outcome. J Infect Dis 2009 ; 200 : 1002–1011. [CrossRef] [PubMed] [Google Scholar]
  18. Lewis RE, Albert ND, Liao G, et al. Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis. Antimicrob Agents Chemother 2010 ; 54 : 1298–1304. [CrossRef] [PubMed] [Google Scholar]
  19. Lanternier F, et al. Mucormycose : résultats de l’étude Ambizygo. San Francisco : ICAAC, 2012 (abstract M-1707). [Google Scholar]
  20. Skiada A, Lanternier F, Groll AH, et al. Diagnosis and treatment of mucormycosis in patients with haematological malignancies : guidelines from the 3rd European Conference on Infections in Leukemia (ECIL 3). Haematologica 2012 ; 14 septembre (online). [PubMed] [Google Scholar]
  21. Almyroudis NG, Sutton DA, Fothergill AW, et al. In vitro susceptibilities of 217 clinical isolates of zygomycetes to conventional and new antifungal agents. Antimicrob Agents Chemother 2007 ; 51 : 2587–2590. [CrossRef] [PubMed] [Google Scholar]
  22. Ibrahim AS, Gebremariam T, Schwartz JA, et al. Posaconazole mono- or combination therapy for treatment of murine zygomycosis. Antimicrob Agents Chemother 2009 ; 53 : 772–775. [CrossRef] [PubMed] [Google Scholar]
  23. Greenberg RN, Mullane K, van Burik JA, et al. Posaconazole as salvage therapy for zygomycosis. Antimicrob Agents Chemother 2006 ; 50 : 126–133. [CrossRef] [PubMed] [Google Scholar]
  24. Verweij PE, González GM, Wiedrhold NP, et al. In vitro antifungal activity of isavuconazole against 345 mucorales isolates collected at study centers in eight countries. J Chemother 2009 ; 21 : 272–281. [CrossRef] [PubMed] [Google Scholar]
  25. Reed C, Bryant R, Ibrahim AS, et al. Combination polyene-caspofungin treatment of rhino-orbital-cerebral mucormycosis. Clin Infect Dis 2008 ; 47 : 364–371. [CrossRef] [PubMed] [Google Scholar]
  26. Spellberg B, Ibrahim AS, Chin-Hong PV, et al. The Deferasirox-AmBisome therapy for mucormycosis (DEFEAT Mucor) study : a randomized, double-blinded, placebo-controlled trial. J Antimicrob Chemother 2012 ; 67 : 715–722. [CrossRef] [PubMed] [Google Scholar]
  27. Ferguson BJ, Mitchell TG, Moon R, et al. Adjunctive hyperbaric oxygen for treatment of rhinocerebral mucormycosis. Rev Infect Dis 1988 ; 10 : 551–559. [CrossRef] [PubMed] [Google Scholar]
  28. Dannaoui E, Schwarz P, Lortholary O. In vitro interactions between antifungals and immunosuppressive drugs against zygomycetes. Antimicrob Agents Chemother 2009 ; 53 : 3549–3551. [CrossRef] [PubMed] [Google Scholar]
  29. Rammaert B, Lortholary O. Immunosuppresseurs et antifongiques : une interaction parfois positive ! Med Sci (Paris) 2010 ; 26 : 747–752. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.